Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Recruiting now · Phase 2
Conditions studied: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
In brief
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.
Key facts
- Study ID
- NCT03297606
- Run by
- Canadian Cancer Trials Group
- People needed
- 720
- Starts
- 2018-03-23
- Expected to finish
- 2027-01-31
- Last updated by the study team
- 2026-03-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cross Cancer Institute — Edmonton, Alberta, Canada (enrolling)
- BCCA - Kelowna — Kelowna, British Columbia, Canada (enrolling)
- BCCA - Vancouver — Vancouver, British Columbia, Canada (enrolling)
- Kingston Health Sciences Centre — Kingston, Ontario, Canada (enrolling)
- London Health Sciences Centre Research Inc. — London, Ontario, Canada (enrolling)
- Ottawa Hospital Research Institute — Ottawa, Ontario, Canada (enrolling)
- University Health Network — Toronto, Ontario, Canada (enrolling)
- The Jewish General Hospital — Montreal, Quebec, Canada (enrolling)
- Allan Blair Cancer Centre — Regina, Saskatchewan, Canada (enrolling)
- Saskatoon Cancer Centre — Saskatoon, Saskatchewan, Canada (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.